Plain-English answer
Medical reimbursement rules in China determine how much of a service, drug, device, test, or admission is paid by basic medical insurance and how much remains with the patient. The rules are not captured by a single national percentage. They depend on the insurance scheme, pooling area, provider level, inpatient versus outpatient setting, local catalogues, deductibles, ceilings, coinsurance, referral rules, and whether the item is inside or outside the relevant reimbursement list.
Benefit design
China's basic medical insurance architecture grew from several schemes: Urban Employee Basic Medical Insurance launched in 1998, the New Rural Cooperative Medical Scheme began in 2003, and Urban Resident Basic Medical Insurance began in 2007. The resident schemes were later integrated into Urban and Rural Resident Basic Medical Insurance. These programs expanded coverage dramatically, but they differ in financing strength and benefit generosity. Employee insurance is generally better funded than resident insurance; inpatient benefits tend to be stronger than outpatient benefits; and reimbursement can change sharply when a patient uses a hospital outside the local pooling area.
A reimbursement calculation often has several layers. The patient first faces a deductible or starting threshold. Eligible spending is then reimbursed at a rate that may differ by hospital level, service type, and insurance category. Reimbursement is usually capped by annual ceilings, and some items remain excluded or only partially covered. Catastrophic medical insurance, medical assistance, commercial insurance, or local supplemental programs may add another layer, especially for high-cost illness, but those layers are uneven.
Payment reform
China is also changing how insurers pay hospitals. The National Healthcare Security Administration has pushed diagnosis-related group payment and Diagnosis-Intervention Packet payment as cost-control and efficiency tools. In 2021, NHSA reported that 30 DRG pilot cities and 71 DIP pilot cities were expected to enter actual payment during that year. Later policy work scaled DRG/DIP payment reform toward broader national implementation. This matters because reimbursement is no longer only a patient benefit question; it is also a hospital revenue question.
Under fee-for-service, hospitals have stronger incentives to provide more billable services. Under DRG or DIP payment with budget constraints, hospitals face pressure to control length of stay, drug use, consumables, and unnecessary procedures. That shift changes the adoption logic for products. A technology that raises the cost of an admission may face resistance unless it reduces complications, readmissions, length of stay, or other costs visible under the payment method.
Patient burden
The phrase "covered by insurance" is therefore incomplete. A rural resident receiving inpatient care at a tertiary hospital in another city, an employee-insured patient using a reimbursed outpatient chronic-disease drug, and a cancer patient seeking a negotiated NRDL medicine may all be insured, but their out-of-pocket exposure can be very different. Studies of China's insurance schemes repeatedly show that reimbursement design affects utilization choices, especially where outpatient reimbursement is weaker or where patients bypass lower-level providers.
For U.S.-China comparison, the key distinction is that China has broad basic insurance enrollment but narrower and more locally variable reimbursement than the phrase universal coverage may imply. The right question is: which pool pays, at what rate, for which eligible item, at which institution, under which referral and settlement rule, after what deductible and before what ceiling?